| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ns8 |
| Uniprot No | P0DTC8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 16-121aa |
| 氨基酸序列 | FHQECSLQSCTQHQPYVVDDPCPIHFYSKWYIRVGARKSAPLIELCVDEAGSKSPIQYIDIGNYTVSCLPFTINCQEPKLGSLVVRCSFYEDFLEYHDVRVVLDFI |
| 预测分子量 | 16.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SARS-CoV-2 NS8重组蛋白的3篇示例参考文献(注：文献为假设性示例，实际研究中请核实真实来源)：
---
1. **标题**：*"Recombinant expression and functional characterization of SARS-CoV-2 NS8 protein"*
**作者**：Zhang Y. et al.
**摘要**：本研究在大肠杆菌系统中成功表达并纯化了重组NS8蛋白，通过体外实验证实其与病毒RNA结合的能力，并发现NS8可抑制宿主细胞I型干扰素信号通路，提示其在免疫逃逸中的作用。
2. **标题**：*"Structural insights into SARS-CoV-2 NS8 and its interaction with host proteins"*
**作者**：Li J. et al.
**摘要**：利用哺乳动物表达系统获得重组NS8蛋白，结合晶体结构分析和免疫共沉淀技术，揭示了NS8与宿主MDA5蛋白的相互作用，阐明其干扰先天免疫应答的分子机制。
3. **标题**：*"SARS-CoV-2 NS8 reprograms host cell metabolism via binding to mitochondrial proteins"*
**作者**：Wang L. et al.
**摘要**：通过重组NS8蛋白的体外功能实验，发现其靶向宿主线粒体蛋白(如TOM70)，导致细胞氧化应激反应增强，为NS8促进病毒复制的代谢调控提供了证据。
---
**注意**：以上文献为示例，实际研究中请通过学术数据库(如PubMed、Web of Science)检索真实发表的论文。若需特定病毒(如其他冠状病毒或病毒属)的NS8研究，请补充说明。
NS8 recombinant protein is derived from the non-structural protein 8 (NS8) of SARS-CoV-2. the virus responsible for COVID-19. NS8 is a small accessory protein encoded by the ORF8 gene, which has drawn significant research interest due to its role in viral pathogenesis and immune modulation. Unlike structural proteins (e.g., spike or nucleocapsid), NS8 is not part of the viral particle but is expressed during infection to interact with host cellular machinery. Studies suggest it may contribute to immune evasion by interfering with interferon signaling or disrupting antigen presentation pathways, though its exact mechanisms remain under investigation.
The production of NS8 as a recombinant protein involves cloning the ORF8 gene into expression systems (e.g., E. coli or mammalian cells), followed by purification for experimental use. Recombinant NS8 enables researchers to study its structure-function relationships, host interaction partners, and potential as a diagnostic or therapeutic target. For instance, it has been utilized in serological assays to detect NS8-specific antibodies in COVID-19 patients, providing insights into immune responses. Additionally, structural analyses of recombinant NS8. including crystallography or cryo-EM, aim to map critical domains involved in viral replication or immune suppression.
NS8’s high genetic variability across SARS-CoV-2 variants has also spurred interest in tracking mutations that might influence viral fitness or clinical outcomes. However, challenges persist in characterizing NS8 due to its low abundance in infected cells and tendency to aggregate during recombinant production. Despite these hurdles, NS8 recombinant protein remains a valuable tool for unraveling its biological significance and exploring strategies to counteract its role in COVID-19 pathogenesis. Ongoing research continues to clarify its contributions to viral persistence and severity, potentially informing future antiviral therapies or vaccine designs.
×
